[주요 연구분야]
- 의약품 전주기(제조·허가·급여·유통·사용 등) 관리 제도, 제약산업 정책
Pharmaceutical industry policies related to drug life cycle management
- 신약 등 의약품에 대한 환자 접근성 및 보험재정에 미치는 영향 분석
Impact of new drug entries on patient access and health insurance budget
- 건강보험 의약품의 급여, 가격결정 및 사후관리 제도 합리화 방안 등
Rationalization of NHI drug reimbursement, pricing, and management systems.

[주요 수행과제]
약품비 관리 및 산업육성 종합 로드맵 도출 (2024)
치료군별 약품비 지출현황 분석 및 합리화 방안 (2024)
국내 제약산업 선진화 및 제네릭의약품 활성화 방안 (2023)
기등재 의약품 급여기준 확대 제도의 효율적 운영 방안 (2023)
우리나라 신약의 약품비 지출 현황 분석 및 합리화 방안 (2023)
의료기기 임상시험 전문인력 양성을 위한 임상교육프로그램 (2023)

Yoo SL. (2025). Timely access to new drugs in a single-payer system: policy analysis from South Korea’s reimbursement framework. Expert Review of Pharmacoeconomics & Outcomes Research, 10.1080/14737167.2025.2561020

Yu SR. (2025). Determinants of budget limits for new drugs in Korea: An empirical analysis of policy and market influences. International Journal of Healthcare Management, 10.1080/20479700.2025.2520933.

Yu SR. (2025). Policy Effectiveness in Managing Drug Shortages: Evidence from South Korea (2015–2024). World Medical & Health Policy. 10.1002/wmh3.70024.

Yu SR. (2025). Improving the Reimbursement Process for New Drugs: A Case Study of a Two-Waiver System in South Korea. Journal of Evaluation in Clinical Practice, 31(3), e70074.

Yu SR, Choi SY. (2025). New Drug Expenditure by Therapeutic Area in South Korea: International Comparison and Policy Implications. Healthcare 2025, 13, 468

Yu SR, Lee JH. (2024). Analysis of Drug Pricing Drivers under South Korea's Pharmaco-Economic Evaluation Exemption Policy (2015-2022). Front. Frontiers in Pharmacology, 15.

Yu SR (2024). Recent Trends and Implications of China’s Drug Reimbursement System. Dongduk Pharm. Res., 28.

Yu SR (2024). Analysis of Price Reduction Execution Suspension Products (Before and After the Implementation of the Settlement System). J. Korean Academy of Social & Managed Care Pharmacy,12(2). 107-118

Lee JE, Yu SR, Seo DC (2024). Exploring Pharmaceutical Dispensing and Delivery Methods in the Era of Electronic Prescriptions. Journal of Pharmaceutical Policy Research. 17(1). 47-64

Yu SR. (2024). Investigation of Drug Quality Control Violations and System Improvement Recommendations. Dongduk Pharm. Res., 26.

Yu SR, Lee JH. (2023). Priceincrease negotiations to address drug shortages in South Korea’s national health insurance. Front. Frontiers in Pharmacology, 14.

Yu SR (2023). Analysis of Domestic and International Trends and Implications of Severe Disease Treatment Cost Support Policies. J. Korean Academy of Social & Managed Care Pharmacy,11(1). 39-51

Lee JH, Yoo SL. (2022). Pricing and reimbursement policy for new orphan drugs in South Korea: focused on patient accessibility and budget impact. Expert Opinion on Orphan Drugs, 10(1):23-28

Lee SH*, Yoo SL*, Bang JS, Lee JH. (2020). Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007-2019). Int J Environ Res Public Health, 17(9):2991

Cho E*, Yoo SL*, Kang YJ, Lee JH. (2020). Reimbursement and pricing of regenerative medicine in South Korea: key factors for achieving reimbursement. Regen Med, 15(4):1550-1560

Yoo SL et al. (2019) Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System. Int J Environ Res Public Health, 16(2):288

Lee SM, Jung JH, David Suh, Jung YS, Yoo SL et al. (2019). Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries. BioDrugs, 33(4):423-436